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Fibrocytes are supposed to be a circulating connective tissue
cell progenitor, which consists of a novel population of
peripheral blood cells. This distinct population of blood-
borne cells shares markers of leukocytes as well as
mesenchymal cells. Accumulating evidence indicates that
fibrosis is characteristic of progressive chronic kidney
diseases of any etiologies, resulting in kidney failure. We have
uncovered that CCR7-positive fibrocytes migrate into the
kidney in response to secondary lymphoid tissue chemokine
(SLC/CCL21) and contribute to kidney fibrosis induced by
unilateral ureteral obstruction in mice. In addition, the
blockade of CCL21/CCR7 signaling by anti-CCL21 antibodies
reduced kidney fibrosis, which was confirmed by a decrease
in fibrosis in CCR7-null mice with concomitant reduction in
macrophage recruitment along with reduced renal
transcripts of monocyte chemoattractant protein-1 (MCP-1/
CCL2). These findings suggest that fibrocytes dependent on
CCL21/CCR7 signaling pathways contribute to the
pathogenesis of kidney fibrosis, thereby providing that
regulating fibrocytes may provide a novel therapeutic benefit
for kidney fibrosis.
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Fibrocytes, originally identified as a circulating bone marrow-
derived, CD34þ cell population of fibroblast-like cells in
1994, was reported to infiltrate from inflammatory exudates
into subcutaneously implanted wound chambers.1 Fibrocytes
uniquely comprise a minor fraction of the circulating pool of
leukocytes (less than 1%) and share the markers of leukocytes
as well as mesenchymal cells (e.g., type I collagen).2,3 As both
of fibrocytes and bone marrow stroma express CD34,
fibrocytes were at first thought to consist of scaffold to
support normal hematopoiesis.4 However, accumulating
evidence suggests that fibrocytes are a strong candidate for
participating in organ fibrosis associated with conditions,
such as pulmonary fibrosis, bronchial asthma, skin wounds,
and intimal hyperplasia, even though the intracellular
mechanisms leading from fibrocytes to fibrosis remain
unclear5–11 (Table 1). In relation with human diseases,
fibrocytes contribute to nephrogenic fibrosing dermopathy
as well as burns.9,10 A recent study reveals that the
impairment of fibrocytes caused by the loss in otospiralin
leads to abnormal cochlear physiology and auditory func-
tion.12 In addition, fibrocytes are characterized as circulating
adipocyte progenitors as well as fibroblasts and myofibro-
blasts.10,13 Transforming growth factor (TGF)-b, serum
amyloid P, and aggregated IgG influence fibrocyte function
and differentiation.10,14,15 However, the detection and role of
fibrocytes in the progressive fibrosis in the kidney remains
investigated.
Fibrosis is a characteristic pathological feature that
determines the prognosis of diseases independent of their
etiologies. Kidney diseases progress to end-stage failure,
showing pathological characteristics including glomerulo-
sclerosis and interstitial fibrosis.1,2 The histological picture of
interstitial fibrosis is characterized by tubular atrophy and
dilation, interstitial leukocyte infiltration, accumulation of
fibroblasts, and increased interstitial matrix deposition.16 In
this aspect, our recent study has uncovered the evidence that
human peripheral CD14-positive monocytes/macrophages
directly contribute to producing type I collagen, resulting in
fibrogenesis, which are dependent on an amplification loop
of monocyte chemoattractant protein-1 (MCP-1/CCL2)/
CCR2.17 These results may provide a key role of immune-
competent cells for their own promoting and escalating tissue
fibrosis in addition to participating in the inflammatory
cascade. Further, fibrocytes are capable of producing
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profibrotic molecules such as TGF-b as well as collagen.10
These results prompt us to investigate a distinct impact of
fibrocytes on kidney tissue remodeling by secreting fibrogenic
factors in the progression of kidney fibrosis. Here, we focus
on the pathophysiological role of fibrocytes dependent on
chemokine system in kidney fibrosis.
DETECTION OF FIBROCYTES IN PROGRESSIVE INTERSTITIAL
FIBROSIS IN MURINE AND HUMAN KIDNEYS
In progressive kidney fibrosis induced by a ureteral ligation in
mice, CD45- and type I collagen-dual-positive fibrocytes
(CD45þ /ColIþ ) infiltrated the interstitium, especially the
corticomedullary regions (Figure 1a–c).18 The number of
infiltrating fibrocytes increased with the progression of
fibrosis after a ureteral ligation, reaching a peak on day 7
(Figure 1d). To further verify the existence of fibrocytes, dual
immunostainings of CD34 and type I collagen were also
performed. The infiltration of CD34- and type I collagen-
dual-positive fibrocytes was also observed in the interstitium
and correlated with disease progression as determined by
CD45- and type I collagen dual immunostainings.18 In
addition to murine-progressive interstitial fibrosis, CD45þ /
ColIþ fibrocytes infiltrate into human chronic kidney
diseases. The number of infiltrating fibrocytes well correlates
with the intensity of interstitial fibrosis in human various
kidney diseases including diabetic nephropathy (manuscript
in preparation). Further, CD34-positive spindle cells, de-
tected in tubulointerstitial lesions in patients with glomer-
ulonephritis, were closely related with interstitial volume, but
not with kidney function.19
FIBROCYTES AND CHEMOKINE SYSTEM
Recent studies demonstrate that chemokine/chemokine
receptor systems on fibrocytes are involved in the recruitment
of circulating fibrocytes to sites of fibrosis.3,5,10 It is of note
that fibrocytes, isolated from human and mice, express
chemokine receptors such as CCR2, CCR3, CCR5, CCR7,
and CXCR4.3,5,10 Intradermal instillation of secondary
lymphoid tissue chemokine (SLC/CCL21) was firstly de-
scribed to induce the recruitment of fibrocytes at the injected
site.7 The migration of fibrocytes to the lung has been
demonstrated to be dependent on signaling pathways of
CXCL12/CXCR4 or CCR2.3,5 CCR7-expressing fibrocytes,
also positive for type I collagen (CCR7þ /ColIþ ), were
detected in diseased kidneys 7 days after a ureteral ligation in
wild-type mice.18 Infiltrating fibrocytes (37.8%) expressed
CCR7 (number of CCR7þ /ColIþ divided by the number of
CCR7þ or CXCR4þ or CCR2þ /ColIþ ). In wild-type mice,
the ratio of CCR7þ /ColIþ cells in obstructed kidneys was
increased to 7.9% of the total isolated renal cells compared
with that in normal kidneys (0.25%) and contralateral
kidneys (0.21%). Of these CCR7-expressing fibrocytes in
obstructed kidneys, 66.5% of cells were CXCR4þ /CCR2þ ,
16.8% of cells were CXCR4þ /CCR2, 4.3% of cells were
CXCR4/CCR2þ , and 12.4% of cells were CXCR4/CCR2.
In contrast, the percentage of CCR7-negative collagen-
producing cells (CCR7/ColIþ ) increased to 26.7% of the
total isolated renal cells from obstructed kidneys.
A ligand for CCR7, secondary lymphoid tissue chemokine
(SLC/CCL21), which is a member of the CC chemokine
family, remains to be investigated in the progression of
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Figure 1 | Detection of fibrocytes in progressive fibrosis in kidney. In wild-type mice, CD45- and type I collagen-dual-positive fibrocytes
infiltrated the interstitium, especially the corticomedullary regions after ureteral ligation (a, CD45; b, merge; c, type I collagen (arrowheads);
CD45- and type I collagen-dual-positive fibrocytes; CD45þ /ColIþ ). (d) The number of infiltrating fibrocytes dual positive for CD45 and
type I collagen was reduced in mice treated with anti-CCL21 antibodies and in CCR7-null mice compared with that in wild-type mice 7
days after ureteral ligation. (e) Dual-positive cells for CCR7 and type I collagen were also reduced by the administration of anti-CCL21
antibodies. Values are the mean7s.e.m. *Po0.05 compared with normal mice, **Po0.05 compared with wild-type mice.
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kidney fibrosis. CCL21 has been reported to act as a
chemotactic stimulus for fibrocytes.18,20 In humans as well
as in mice, CCL21 is constitutively abundant in lymphoid
tissues, particularly in the lymph nodes and spleen. It is of
note that CCL21 is also expressed at lower levels in some
non-lymphoid tissues, including the lung.21 CCL21 expres-
sion is relatively localized in high endothelial venules (HEVs)
in lymph nodes under physiological conditions21 as well as in
non-lymphoid tissues under inflammatory conditions.22 In
fact, CCL21- and MECA79-dual-positive vessels were found
in synovial tissues from patients with rheumatoid arthritis.23
The number of CCL21- and MECA79-dual-positive HEV-like
vessels as well as in situ expression of CCL21 mRNA
increased with disease progression after ureteral ligation.18
HEVs express certain chemokines, such as EBI1-ligand
chemokine/CCL1924 as well as CCL21, that can activate
CCR7-expressing cells, even though CCL19 expression
remained investigated in the previous report.18 Concomi-
tantly, MECA79-positive HEV-like vessels located at the
corticomedullary junction were detected and associated with
interstitial leukocyte infiltration in human glomerulonephri-
tis.25 These findings suggest that CCR7-expressing circulating
fibrocytes infiltrate the kidney via CCL21-positive HEV-like
vessels, resulting in the contribution to kidney fibrosis.
BLOCKADE OF CCL21/CCR7 SIGNALING REDUCED INTERSTI-
TIAL FIBROSIS IN THE KIDNEY
The impact of CCL21/CCR7 signaling on progressive kidney
interstitial fibrosis was further examined. Mean interstitial
fibrosis as well as the amount of hydroxyproline was reduced
by almost 50% in mice treated with anti-CCL21 antibodies
compared with that in wild-type mice 7 days after an ureteral
ligation, which was confirmed by the similar reduction in
CCR7-null mice (Figure 2).18 Accordingly, on the basis of
finding that treatment with anti-CCL21 antibodies or CCR7
deficiency resulted in over 50% reduction in the number of
CD45- and type I collagen-dual-positive fibrocytes, thereby
CCL21/CCR7 signaling is thought to be the major pathway
attracting fibrocytes into the kidney in this particular model.
In addition, ureteral ligation enhanced the pro-a1 chain of
type I collagen mRNA expression as well as transcripts of
TGF-b1, which was also downregulated by the inhibition of
CCL21/CCR7 signaling.
Moreover, blockade of CCL21/CCR7 signaling reduced the
number of CCR7-expressing fibrocytes as well as CCR2-
expressing fibrocytes in immunohistochemical studies. A
recent study reported that CCL2/CCR2 signaling mediated
recruitment of CCR2-expressing fibrocytes to the alveolar
space after administration of fluorescein isothiocyanate,
resulting in pulmonary fibrosis.3 Fibrocytes have been
considered to be capable of producing MCP-1/CCL2 under
pathological fibrotic conditions.10 Therefore, inhibiting the
infiltration of CCR7-expressing fibrocytes appears to decrease
the infiltration of CCR2-expressing fibrocytes through
suppression of MCP-1/CCL2 production, thereby contribut-
ing to more effective protection from kidney fibrosis
(Figure 3).26,27 In contrast, the infiltration of CXCR4-positive
fibrocytes was not reduced by the blockade of CCL21/CCR7.
Therefore, further studies will be required to elucidate the
precise mechanisms that other chemokine/chemokine recep-
tor pathways may also be involved in the recruitment and
activation of fibrocytes, resulting in progressive fibrosis.
FIBROCYTES AND EPITHELIAL–MESENCHYMAL TRANSITION
Detailed molecular mechanisms involved in progressive
organ fibrosis are not fully uncovered. Currently, resident
fibroblasts, epithelial–mesenchymal transition-derived fibro-
blasts/myofibroblasts, and monocytes/macrophages are
thought to be participants in the pathogenesis of kidney
fibrosis.17,28,29 In addition, Iwano et al.28 reported that 15%
were derived from CD34-negative fibroblasts in bone
marrow, whereas 36% of renal fibroblasts found in a UUO
model were derived from epithelial–mesenchymal transition.
Interestingly, circulating fibrocytes express CD34; however,
fibrocytes reduce the expression of CD34 on the surface as
they become more specialized.10 Moreover, the stimulation of
TGF-b1 decreases the expression of cell surface CD34.
However, the relation of fibrocytes with epithelial–mesench-
ymal transition-derived fibloblasts and CD34-negative fibro-
blasts remains investigated. Recent reports raise the
possibility that these participants may interact with each
other. TGF-b1 may play a key role in this aspect. TGF-b1,
which could be produced by fibrocytes,2 is a well-character-
ized inducer of epithelial–mesenchymal transition in tubular
epithelial cells.30 Concomitantly, fibrocytes further differ-
entiate to contractile myofibroblasts co-existant with TGF-
b1.10 Alternatively, a very recent study revealed that an
average of 32% of all interstitial a-smooth muscle actin-
positive myofibroblasts were derived from the bone marrow.
Functional bone marrow-derived myofibroblasts infiltrate in
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Figure 2 | Inhibition of CCL21/CCR7 signaling ameliorated
progressive fibrosis in the kidney. CCL21/CCR7 signaling reduced
the mean (a) interstitial fibrosis and the total (b) tissue collagen
content (hydroxyproline) 7 days after ureteral ligation. Values are the
mean7s.e.m. **Po0.05 compared with wild-type mice.
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the post-ischemic renal interstitium and are involved in
extracellular matrix.31 Therefore, further study would be
required to examine the fundamental properties, differentia-
tion potential, and mutual interactions of participants in
progressive organ fibrosis in depth (Figure 3).
FIBROCYTES IN OTHER DISEASES
Fibrocytes are now considered to be involved in various
conditions including tumor biology, immunostimu-
latory properties, infection, and scleroderma (Table 1).10
Dual-positive spindle-shaped cells for CD34 and procollagen
are present at a thickened dermins in a patient with
nephrogenic systemic fibrosis, which is closely related to
renal insufficiency.32 A more recent study revealed a
population of small spindle-shaped fibroblasts that were
highly proliferative and expressed collagen I and a-smooth
muscle actin (myofibroblast markers), CD34 (a precursor
marker), and CD45 (a hematopoietic marker) in ischemic
cardiomyopathy in mice. Importantly, serum amyloid P
may be an important regulator in the linkage between
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Figure 3 | Schema for CCL21/CCR7-dependent fibrosis in the kidney. CCR7-expressing circulating fibrocytes, infiltrated in the kidney
via SLC/CCL21-positive HEV-like vessels, take part in the pathogenesis of fibrosis not only by synthesizing collagen but also by regulating
macrophages through MCP-1/CCL2 production and epithelial–mesenchymal transition through the production of TGF-b1.
Table 1 | Characteristics of fibrocytes
Cell markers Secreted products Functional roles
a-Smooth muscle actin (a-SMA) Collagen I Wound repair
Collagens I and III Matrix metalloproteinase-9 (MMP-9) Burn
Procollagen I Proinflammatory cytokines/chemokines Angiogenesis
Fibronectin Tumor necrosis factor-a (TNF-a) Antigen presenting properties
Vimentin Interleukin-a (IL-1a) Granuloma
Propyl 4-hydroxylase IL-6 Tumor biology
CD antigens IL-8/CXCL1 Infection
CD11a (LFA-1) Macrophage inflammatory protein 2(MIP-2)/CXCL2 Chronic pancreatitis
CD11b (MAC-1) Monocyte chemoattractant protein-1 (MCP-1)/CCL2 Chronic cystits
CD13 (aminopeptidase N) MIP-1a/CCL3 Nephrogenic systemic fibrosis
CD18 Platelet-derived growth factor A (PDGF-A) Kidney fibrosis
CD34 Transforming growth factor-a (TGF-a) Scleroderma
CD45RO TGF-b1 Asthma
CD54 (ICAM-1) Connecting tissue growth factor (CTGF) Pulmonary fibrosis
CD58 (LFA-3) Macrophage-colony stimulating factor (M-CSF) Acute lung injury
CD71 Vascular endothelial cell growth factor (VEGF) Intimal hyperplasia
CD80 (B7.1) Granulocyte-macrophage colony stimulating factor (GM-CSF) Cochlear physiology
CD86 (B7.2) Basic fibroblast growth factor (bFGF) Fibrocyte differentiation
MHC class II Angiogenin Myofibroblast
DP Hepatocyte growth factor Fibroblast
DQ Otospiralin Adipocyte
DR Fdp
Chemokine receptor Leukocyte specific protein 1 (LSP-1)
CXCR4 (CD184)
CCR2
CCR3
CCR5 (CD195)
CCR7 (CDw107)
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inflammation and nonadaptive fibrosis through the modula-
tion of proliferative spindle-shaped fibroblasts in the heart.33
CONCLUSION
An insight of fibrocytes dependent on CCL21/CCR7 signal-
ing pathways through HEV-like vessels has shed light on the
novel pathogenesis of progressive organ fibrosis including
kidney fibrosis. The most compelling part in our previous
study was that the inhibition of CCL21/CCR7 signaling
ameliorated progressive kidney fibrosis by almost 50%.18 In
addition to inhibiting chemokine system, our recent
unpublished data suggest that renin–angiotensin aldosterone
system plays a role in the activation of fibrocytes, suggesting
the blockade of renin–angiotensin aldosterone system might
provide a beneficial therapeutic approach, at least in part, via
the inhibition of fibrocyte activation. Deeper knowledge of
signals for the recruitment and activation of fibrocytes during
the progression of fibrosis may provide a key to better
therapeutic benefit for combating fibrosis in humans.
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